ICYMI: Following Clear Affordability Message from Voters, the INSULIN Act is Again Offered as an Immediate Solution
(Washington, DC) – In case you missed it: Several of the nation’s largest health care advocacy organizations recently sent letters to President Donald Trump, Speaker of the House Mike Johnson (LA-04), House Minority Leader Hakeem Jeffries (NY-08), Senate Majority Leader John Thune (R-SD) and Senate Democratic Leader Chuck Schumer (D-NY) urging the group to support and immediately pass Senator Shaheen’s bipartisan INSULIN Act to cap the cost of insulin at $35 a month during the lame duck session. The letters highlight the excessively high cost of the life-saving medication and come after historic midterm elections where the American public made it overwhelmingly clear that they want to see real solutions to the affordability crisis. Both letters continue a trend of growing support for the INSULIN Act, where in September senators on both sides of the aisle increasingly pointed to the legislation as an immediate step Congress can take to lower health care costs.
The letters were signed by the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care & Education Specialists, Beyond Type 1, Blue Circle Health, Breakthrough T1D, Children with Diabetes, Diabetes Leadership Council, Diabetes Patient Advocacy Coalition, Endocrine Society, National Black Nurses Association, National Kidney Foundation, Prevent Blindness, T1D Exchange, The Diabetes Link and The diaTribe Foundation.
The letter to President Trump can be found HERE and the letter to Congressional leadership HERE.
“Voters sent a clear message this election that Congress needs to take urgent action to lower costs for American families,” said Senator Shaheen. “With my INSULIN Act, we have a bipartisan opportunity right in front of us to deliver meaningful relief by capping monthly insulin costs at just $35. The bill has strong support from Republicans and Democrats in both the House and Senate—getting it across the finish line is a top priority of mine before year's end.”
Shaheen’s bipartisan Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act would cap monthly out-of-pocket insulin costs at $35 for Americans with insurance, expanding the effective price cap for Americans on Medicare. Shaheen has championed efforts to lower insulin costs throughout her time in office, and the bill is closer than ever before to passing out of the U.S. Senate. In July, the INSULIN Act advanced out of the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee, and in September companion legislation was introduced in the U.S. House of Representatives.
Senator Shaheen has worked tirelessly to lower health care costs for Granite Staters and Americans. As co-chair of the U.S. Senate Diabetes Caucus, Senator Shaheen has consistently pressed to hold insulin manufacturers, insurers and pharmacy benefit managers accountable for the skyrocketing cost of life-saving insulin and otherwise support patients and families facing diabetes. Polling released from the American Diabetes Association this summer found that 40% of respondents who rely on insulin report paying more than $150 per month for insulin, and 76% of respondents across political parties support a $35 limit on cost sharing for insulin.
###